Asaf Danziger has served as Chief Executive Officer of Novocure since 2002 and has been a director of Novocure since 2012. Mr. Danziger has led the company and the development of TTFields therapy from preclinical testing through regulatory approvals to commercial sales in Europe and the United States. From 1998 to 2002, Mr. Danziger was Chief Executive Officer of Cybro Medical, a subsidiary of Imagyn Medical Technologies. Mr. Danziger holds a B.Sc. in material engineering from Ben Gurion University of the Negev, Israel.
clinical trialsOur mechanism of action is broadly applicable across a variety of solid tumors.
publicationsWe have more than 15 years of research and multiple peer-reviewed publications with pre-clinical data in 15 cancer types and clinical data in eight cancer types.
novocuretrial.comThe science of Tumor Treating Fields extends beyond glioblastoma. We are conducting clinical trials in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.